{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.8","upperLimit":"39.4","value":"36.0"},{"groupId":"OG001","lowerLimit":"38.1","upperLimit":"46.9","value":"43.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG000","title":"Rucaparib 600 mg Tablets"},{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG001","title":"Placebo Tablets"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat: All patients randomized","reportingStatus":"POSTED","timeFrame":"All patients were followed for survival up to approximately 8.2 years.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}